EUVIMEDEUVIMED entdecken
MetaanalyseOpen Access · CC BY 4.0

Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure

Luke Fostvedt, Jian Liu, Xiaoxing Wang, Yinhua Li, Jillian Johnson, Linda Wood, Martin Dowty, Bimal Malhotra, Hernan Valdez, Timothy Nicholas, Wei Xue

Clinical Pharmacology in Drug Development · 2024-10 · 13 (10) · 1098-1107

DOI: 10.1002/cpdd.1465 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Clinical Pharmacology in Drug Development, online erschienen am 30.08.2024. Verfasst von Luke Fostvedt und 10 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer, Inc, Cambridge, MA, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Cytochrome P-450 CYP2C9, Area Under Curve, Polymorphism, Genetic. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer Inc., Pfizer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abrocitinib is a selective Janus kinase 1 inhibitor approved for the treatment of atopic dermatitis. It is metabolized primarily by cytochrome P450 (CYP) 2C19 (approximately 53%) and CYP2C9 (approximately 30%), which form 2 active metabolites. The pharmacologic activity of abrocitinib is attributable to the unbound exposures of abrocitinib and those metabolites with active moiety area under the plasma concentration–time curve (AUC) considered the best measure of the total pharmacological effect. The effect of CYP2C19 and/or CYP2C9 genotypes on abrocitinib and active moiety exposures were evaluated using a meta‐analysis of the noncompartmental estimates of exposure pooled from 10 clinical studies. A linear mixed‐effects model was developed on the basis of the power model to evaluate the effect of CYP2C19 and/or CYP2C9 genotypes on exposure (i.e., abrocitinib AUC and peak plasma concentration, active moiety AUC and peak plasma concentration). The genotypes were evaluated individually and as a combined phenotype effect. When evaluating the poor metabolizers of CYP2C19 or CYP2C9 individually, the estimated increases were 44.9% and 42.0% in active moiety AUC, respectively. The combined phenotype models showed a 0.6% decrease, and 25.1% and 10.5% increases in the active moiety AUC for “elevated,” “mixed,” and “reduced” metabolizers, respectively. Overall, the active moiety exposures did not appear to be affected to a clinically meaningful extent by different genotypes of CYP2C19 and/or CYP2C9.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2C9Area Under CurvePolymorphism, GeneticPyrimidinesHumansGenotypeDermatitis, AtopicSulfonamides

Stichwörter der Autor:innen

CYP2C19CYP2C9abrocitinibactive moietypharmacogenomics

Substanzen

Cytochrome P-450 CYP2C19Cytochrome P-450 CYP2C9CYP2C19 protein, humanCYP2C9 protein, humanabrocitinibPyrimidinesSulfonamides

Autor:innen und Institutionen

  • Pfizer, Inc, Cambridge, MA, USA.
  • Pfizer, Inc, Beijing, China.
  • Pfizer, Inc, Groton, CT, USA.
  • Pfizer, R&D, Tokyo, Japan.
  • Pfizer, Inc, New York, NY, USA.
  • Clinical Trial Center, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

Förderung

  • Pfizer Inc.
  • Pfizer

Zitieren

APA

Fostvedt, L., Liu, J., Wang, X., Li, Y., Johnson, J., Wood, L., Dowty, M., Malhotra, B., Valdez, H., Nicholas, T., & Xue, W. (2024). Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure. Clinical Pharmacology in Drug Development, 13(10), 1098-1107. https://doi.org/10.1002/cpdd.1465

Vancouver

Fostvedt L, Liu J, Wang X, Li Y, Johnson J, Wood L, et al. Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure. Clinical Pharmacology in Drug Development. 2024;13(10):1098-1107. doi:10.1002/cpdd.1465

BibTeX
@article{Fostvedt2024,
  author = {Fostvedt, Luke and Liu, Jian and Wang, Xiaoxing and Li, Yinhua and Johnson, Jillian and Wood, Linda and Dowty, Martin and Malhotra, Bimal and Valdez, Hernan and Nicholas, Timothy and Xue, Wei},
  title = {Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters to Evaluate the Impact of CYP2C19 and CYP2C9 Genetic Polymorphisms on Abrocitinib Exposure},
  journal = {Clinical Pharmacology in Drug Development},
  year = {2024},
  volume = {13},
  number = {10},
  pages = {1098--1107},
  doi = {10.1002/cpdd.1465}
}
Kostenlos starten →